Short Course Radical Cure of P. Vivax Malaria in Nepal
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study is designed as a multicentre randomized, open label trial to assess the safety and
efficacy of a low dose short course PQ treatment (3.5mg/kg total dose given over 7 days) in
glucose-6-phosphate dehydrogenase (G6PD) normal patients with P.vivax and P falciparum to
reduce the risk of subsequent P.vivax episodes.